Research programme: cathepsin V inhibitors - Celera GenomicsAlternative Names: Cathepsin V inhibitors research programme - Celera Genomics
Latest Information Update: 05 Sep 2006
At a glance
- Originator Celera Genomics Group
- Mechanism of Action CTSL2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group
- 28 Sep 2000 New profile